Safety and Immunogenicity Study of Therapeutic HSV-2 Vaccine

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

May 9, 2014

Study Completion Date

May 9, 2014

Conditions
Genital Herpes Simplex Type 2
Interventions
BIOLOGICAL

GEN-003 with Matrix M-2

IM administration of GEN-003 Vaccine with 50ug Matrix M-2 Adjuvant.

BIOLOGICAL

GEN-003

IM administration of GEN-003 Vaccine, antigens alone (without adjuvant).

BIOLOGICAL

Placebo

IM administration of 0.5 mL dose of Dulbecco's phosphate buffered saline.

Trial Locations (7)

46202

Indiana University Infectious Disease Research, Indianapolis

77030

Center for Clinical Studies - Houston, Houston

77598

Center for Clinical Studies - Clear Lake/Webster, Webster

97210

Westover Heights Clinic, Portland

98104

UW Virology Research Clinic, Seattle

35294-0006

University of Alabama Vaccine Research Unit, Birmingham

45229-3039

Cincinnati Children's Hospital Medical Center, Cincinnati

Sponsors
All Listed Sponsors
lead

Genocea Biosciences, Inc.

INDUSTRY